RTP Mobile Logo
Interactive Tumor Board: Clinical Investigators Discuss Available Research Shaping the Current and Future Treatment of Colorectal, Gastric and Pancreatic Cancer
Released March 2018

Proceedings from a CME symposium held at the 2018 Gastrointestinal Cancers Symposium. Featuring perspectives from moderator Dr Johanna C Bendell and faculty members Drs Tanios Bekaii-Saab, Peter C Enzinger, Heinz-Josef Lenz, Eileen M O'Reilly and Michael J Overman. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal, gastric and pancreatic cancer.

    OVERVIEW OF ACTIVITY
    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other “non-CRC” gastrointestinal (GI) cancers account for more per annum deaths than those attributed to tumors of the colon and rectum combined. As such, educational opportunities relevant to the clinical management of CRC and the most prevalent non-CRC GI tumors, including gastric and pancreatic cancer, are essential to the general oncologist’s delivery of comprehensive care.

    These video proceedings from a CME meeting held during the 2018 Gastrointestinal Cancers Symposium feature review of actual cases of colorectal, gastric and pancreatic cancer from the practice of the moderator and presentations given by leading investigators in the management of GI cancers. By providing information and practical perspectives on important new developments, this activity will address the most pressing educational needs of practitioners involved in the multidisciplinary management of colorectal, gastric and pancreatic cancer.

    LEARNING OBJECTIVES

    • Review recent data on therapeutic advances and changing practice standards in colorectal, gastric and pancreatic cancer, and integrate this information, as appropriate, into current clinical care.
    • Develop a long-term care plan for individuals diagnosed with metastatic CRC, considering biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
    • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
    • Consider age, PS and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
    • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
    • Describe ongoing research to validate or identify additional biomarkers predictive of response to anti-PD-1/PD-L1 antibodies, and use this information to guide future trial design or routine clinical practice.
    • Recall the design of ongoing clinical trials evaluating novel investigational agents in GI cancers, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GICancers18/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Co-Leader, GI Cancer Program, Mayo Clinic Cancer Center
    Senior Associate Consultant
    Mayo Clinic, Arizona
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, ARMO BioSciences, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Ipsen Biopharmaceuticals Inc, Merck, Roche Laboratories Inc, SillaJen; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly.

    Peter C Enzinger, MD
    Director, Center for Esophageal and Gastric Cancer
    Assistant Professor of Medicine, Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Merck; Consulting Agreements: Astellas Pharma Global Development Inc, Five Prime Therapeutics Inc, Merck, Taiho Oncology Inc.

    Heinz-Josef Lenz, MD
    Professor of Medicine and Preventive Medicine
    J Terrence Lanni Chair in Cancer Research
    Co-Director, USC Center for Molecular Pathways and Drug Discovery
    Keck School of Medicine, University of Southern California
    Associate Director of Adult Oncology
    Co-Director, Colorectal Center
    Scientific Director, Cancer Genetics Unit
    USC Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Merck, Roche Laboratories Inc.

    Eileen M O'Reilly, MD
    Associate Director, Clinical Research
    David M Rubenstein Center for Pancreatic Cancer Research
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Medical College of Cornell University
    New York, New York

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Aptus Clinical, ASLAN Pharmaceuticals, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen, CASI Pharmaceuticals Inc, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Debiopharm Group, Delcath Systems Inc, Eisai Inc, Gilead Sciences Inc, Halozyme Inc, Incyte Corporation, Inovio Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Lilly, MabVax Therapeutics, MedImmune Inc, Merck, Onxeo, PCI Biotech, Roche Laboratories Inc, Sanofi Genzyme, Servier, Silenseed Ltd, SillaJen, Sirtex Medical Ltd, Yakult Honsha Co Ltd; Contracted Research: Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, CASI Pharmaceuticals Inc, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Incyte Corporation, Lilly, MabVax Therapeutics, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    Michael J Overman, MD
    Associate Professor
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Bristol-Myers Squibb Company, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Contracted Research: Amgen Inc, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Other Remunerated Activities: Merck.

    MODERATOR

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Contracted Research: Abbott Laboratories, AbbVie Inc, Agios Pharmaceuticals Inc, Apexigen, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MedImmune Inc, Merck, Nektar, Novartis, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Roche Laboratories Inc, Sanofi Genzyme, Stemcentrx, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology.

    AUDIENCE ENGAGEMENT LIAISON — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2018
    Expiration date: March 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):